SCHEMBL454513

SCHEMBL454513

Cc1ccc(-n2c(C(C)N(C)S(=O)(=O)c3ccc4ccccc4c3)nc3ccccc3c2=O)c(C)c1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
KDM4E B2RXH2 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
MAPT P10636 1/20 0.49
TDO2 P48775 1/20 0.44
IDO2 Q6ZQW0 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.39
LMNA P02545 2/20 0.39
CXCR3 P49682 3/20 0.38
HTR7 P34969 2/20 0.37
C1R P00736 1/20 0.36
PRSS1 P07477 1/20 0.36
HTT P42858 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HPGD P15428 2/20 0.36
PLA2G1B P04054 1/20 0.36
GAA P10253 1/20 0.36
ATG4B Q9Y4P1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL454036 0.93 ALDH1A1 (0.56) ALDH1A1KDM4ESMN1; SMN2MAPTTDO2
SCHEMBL449258 0.91 ALDH1A1 (0.53) ALDH1A1KDM4ESMN1; SMN2MAPTTDO2
SCHEMBL451983 0.91 ALDH1A1 (0.54) ALDH1A1KDM4ESMN1; SMN2MAPTTDO2
SCHEMBL448424 0.90 ALDH1A1 (0.53) ALDH1A1KDM4ESMN1; SMN2MAPTTDO2
SCHEMBL449873 0.89 ALDH1A1 (0.51) ALDH1A1KDM4ESMN1; SMN2MAPTTDO2
SCHEMBL451269 0.89 ALDH1A1 (0.51) ALDH1A1KDM4ESMN1; SMN2MAPTTDO2
SCHEMBL448729 0.88 ALDH1A1 (0.49) ALDH1A1KDM4ESMN1; SMN2MAPTTDO2
SCHEMBL450744 0.88 ALDH1A1 (0.49) ALDH1A1KDM4ESMN1; SMN2MAPTTDO2
SCHEMBL452757 0.88 ALDH1A1 (0.51) ALDH1A1KDM4ESMN1; SMN2MAPTTDO2
SCHEMBL448618 0.88 ALDH1A1 (0.51) ALDH1A1KDM4ESMN1; SMN2MAPTTDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2012-03-15 US claimed
EP-1521746-B1 QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2011-04-27 EP claimed
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2012-03-15 US disclosed
EP-1521746-B1 QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2011-04-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors NR1H4, NR1H2, NR1H3 ALDH1A1 3161/4885KDM4E 3717/4885SMN1; SMN2 4873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.